Much conversation and research were going on over a couple of years on a new class of drug- CGRP inhibitors and its potential to prevent and treat a migraine.
The US FDA has approved the first treatment- Aimovig (erenumab-aooe) to prevent migraine in adults, belonging to the new class of drug called CGRP inhibitors. Aimovig is developed by Amgen.
Read the article to know about Aimovig and developments in the popular area of migraine research- CGRP inhibitors.
Leave a reply